Purpose. Carbapenemase-producing organisms (CPOs) can be resistant to almost all b-lactams and represent an increasing threat in healthcare facilities. Detection of these organisms in routine diagnostic laboratories is difficult; here we evaluate four commercially available CPO detection assays and assess their suitability for the clinical laboratory. Results/Key Findings. The commercial assays performed well, with high sensitivities (96.2-100 %) and specificities (all, 100 %). The RapidEC CarbaNP and Acuitas Resistome were able to detect the broadest range of carbapenemase genotypes. The RESIST-3 O.K.N. and Xpert CarbaR had the shortest turnaround times, whilst the RapidEC CarbaNP was the only assay included in this study that could detect previously undescribed genotypes.
INTRODUCTION
Carbapenemases are b-lactamases that can hydrolyze penicillins, cephalosporins and carbapenems. Many types of carbapenemase enzymes have been described that have different inhibition mechanisms and varying abilities in vitro, and in vivo, to hydrolyze the different b-lactam groups [1] . Carbapenemase-producing organisms (CPOs) are multidrug-resistant and infections caused by these organisms have been shown to be associated with increased morbidity and mortality [2] . Rapid and accurate detection of CPOs can aid appropriate clinical management of patients and allow the implementation of infection control procedures that can prevent transmission of the resistant organisms. Outbreaks of CPOs have been shown to be associated with substantial costs for NHS trusts resulting from infection control interventions, increased treatment costs, increased laboratory costs and reduced revenue associated with lost bed days and reduced capacity to perform elective surgical procedures [3] .
The many different types of carbapenemases can be classified into three main groups based on molecular structure: class A, which contain serine at the enzymatic active site (e.g. SME, IMI, NMC, GES and KPC); class B, the metallob-lactamases (e.g. IMP, NDM, VIM and GIM); and class D, the OXA-like b-lactamases (e.g. OXA-48, OXA-181) [4] . The prevalence rates of the different carbapenemase types vary throughout the world, and the most common in the UK are currently KPC, OXA-48, NDM and VIM [5] .
Detection of CPOs in the routine diagnostic laboratory is challenging and a gold-standard testing methodology has not been established. The large number of different genotypes that are present worldwide are associated with many different phenotypes and few, if any, of the detection methods available to routine diagnostic laboratories can detect all carbapenemase types with high sensitivity and specificity [6] . Culture-based methods can be associated with poor turnaround times (TATs) and can lack sensitivity due to carbapenemase-positive organisms that have carbapenem minimum inhibitory concentrations (MICs) below clinical breakpoints [7] . Methods that use MICs that are lower than clinical breakpoints to improve sensitivity often lack specificity due to carbapenem non-susceptible carbapenemase-negative organisms [8] . Therefore, to allow accurate detection of the highest possible number of CPOs in the diagnostic laboratory, a highly sensitive culture-based screen is often followed by confirmatory assays with improved specificity, or reference laboratory referral, which adds to the cost and TAT of identification.
Molecular methods for the detection of CPOs are rapid, and have been shown to be highly sensitive and specific for the detection of the most common carbapenemase types [9] . However, due to limitations on the numbers of targets that can be amplified in the assays commonly available to routine diagnostic laboratories (typically four to six), users must choose detection of a carbapenemase range most relevant to their setting. If they are used as standalone tests, these assays will miss carbapenemase types thought to be of low prevalence, and any newly described, emerging types, hence risking the release of false-negative results and delayed detection of possible outbreaks. Molecular methods that allow detection of an increased number of targets are available [9] , but are often limited to reference and/or research facilities due to cost and/or the expertise required to perform the assay and interpret the results.
Detection methods based on the hydrolysis of a carbapenem should, in theory, be able to detect all carbapenemase types, including those that have previously not been described. However, there is debate over which carbapenem should be used as the substrate, as carbapenemases hydrolyze different carbapenems with varying efficiency [10] , making it unlikely that a single substrate can be used to reliably detect all carbapenemase groups. Detection of carbapenemase types with weak hydrolyzing abilities, such as GES-5, SME-1 and some OXA genotypes, is particularly difficult using methods based on carbapenem hydrolysis [10] . In addition, the accuracy of these assays can be complicated further by biological, genetic, or cellular factors associated with the organism -for example, bacterial colonies that are highly mucoid in vitro have previously been shown to result in false-negative results [11] , possibly due to less free enzyme being available under such conditions. In addition, the results from hydrolysis-based methods do not always provide information on the carbapenemase type detectedinformation that is useful for both outbreak identification and management.
The Royal Free London NHS Foundation Trust is a tertiary referral centre with a diverse, international patient population. Following national guidance [12] , we run a programme of active CPO screening for high-risk patients, which currently includes universal screening of the intensive care unit (ICU) patients and risk-based screening of private, renal, haematology, infectious diseases (ID), stroke, hepatology and oncology patients. In addition, individual patients are screened if risk factors, such as contact with a positive patient or recent healthcare abroad in a high-risk country, are identified. Since introducing screening in July 2013, over 50 000 samples have been tested and, in 2015, a CPO prevalence of 0.8 % amongst all patients screened was found. The most commonly detected genotype was OXA-48, followed by NDM, from Enterobacteriaceae and VIM from Pseudomonas aeruginosa. In addition, more unusual types, including IMP, IMI and GES-5 have occasionally been detected.
The methodology used until now has been culture-based, with a long TAT (5-10 days) and low specificity due to an inability to directly detect OXA-48 type carbapenemases, which need to be confirmed by the Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) reference unit, Public Health England (PHE). Here we describe the evaluation of four carbapenemase detection methods (RapidEC Carba NP, RESIST-3 O.K.N., Xpert Carba-R and Acuitas Resistome) and propose an algorithm that integrates these methods to optimize CPO detection and laboratory workflow.
METHODS Isolates
A total of 95 non-duplicate, multidrug-resistant organisms isolated from either clinical (26) or screening samples (69) received at The Royal Free London NHS Foundation Trust between March 2011 and December 2016 were included in this study ( Table 1 ). All of the isolates were multidrug resistant and identified as suspected CPO based on results from in-house antimicrobial susceptibility testing (AST) using the BD Phoenix and/or disc diffusion MbL/KPC results (using KPC and MbL Confirm kits, Rosco Diagnostica). Confirmation of CPO status was performed at the Reference Laboratory (AMRHAI, PHE). Isolates were stored at À80 C, from which they were sub-cultured a maximum of two times prior to testing.
The isolates included in this study did not represent consecutive CPOs isolated within the laboratory, but were instead selected to challenge the commercial assays with a high number of positive isolates that, proportionally, represented the different CPO genotypes that are detected at The Royal Free London NHS Foundation Trust.
RapidEC CarbaNP (Biomerieux)
The RapidEC CarbaNP (ref. 415418) test is performed from isolates and uses the direct detection of carbapenem hydrolysis by carbapenemase enzymes to detect CPOs, independently of the genotype present. The assay was performed according to the manufacturer's instructions; the inoculum was prepared by comparison with the turbidity standard provided within the assay using a loopful of colony grown on a Mueller-Hinton agar plate for 18-24 h, after two subcultures from isolates that had been stored at À80
C. Reactions were read after 30 and 120 min of incubation. Colour changes from red to yellow-orange were interpreted as follows: any colour change from red to yellow-orange, compared to the control well, was rated as a positive test result, irrespective of the yellow-orange colour intensity. The reading guide provided by the manufacturer was used to ensure correct interpretation. The test was performed by experienced personnel and all results were read by scientists who were blinded to the carbapenemase status of the organism.
Following review of the initial results, CPO-positive isolates that gave false negative results were retested using a much heavier inoculum following a method previously described [11] that has been shown to increase the sensitivity of the assay.
Xpert Carba-R (Cepheid)
The Xpert Carba-R is a real-time PCR that is used for the detection and differentiation of bla KPC , bla NDM , bla OXA-48-like , bla VIM and bla IMP-1 gene sequences. The assay was performed from isolates using a previously described dilution method [13] . In brief, a 0.5 McFarland standard of the organism was diluted 1 : 10 in PBS, and 10 µl was then added to a sample reagent vial supplied with the kit. Then 1.7 ml of the reaction mix was added to the Xpert Carba-R assay cartridge, which was loaded immediately onto a GeneXpert PCR machine for testing. The PCR conditions and reagents were as described by the Manufacturer.
RESIST-3 O.K.N. (Coris Bioconcept)
The RESIST-3 O.K.N. assay is a single immunochromatography test for the simultaneous, independent identification of OXA-48-like, KPC-like and NDM-like carbapenemases directly from bacterial colonies. A nitrocellulose membrane provided in the kit is sensitized, in individual positions, with monoclonal antibodies directed against epitopes of the OXA-48-like, KPC-like and NDM-like carbapenemase groups and a control antigen. In addition, the strip contains conjugates, directed against a second epitope of each carbapenemase group, coupled to colloidal gold particles. When the suspended bacteria are added to the membrane, both the sample material and solubilized conjugates migrate along the strip by passive diffusion. Any carbapenemase conjugate present remains bound to the corresponding line of adsorbed monoclonal antibody, allowing the visualization of a positive result.
The assay was performed according to manufacturer's instructions; in brief, isolated pure bacterial colonies from a CLED agar plate were suspended in 10 drops of LY-A buffer provided with the kit. The suspension was mixed well and three drops were added to the sample well of the cassette. The results were read after 15 min at room temperature, and only accepted if the control line was visible.
Acuitas Resistome (OpGen)
Isolates were tested by OpGen Clinical Services Laboratory using the Acuitas Resistome Test (OpGen, Inc., Gaithersburg, MD, USA). The OpGen Acuitas Resistome Test is a microfluidic PCR array that analyses Gram-negative bacilli for approximately 50 antibiotic resistance gene families across several hundred variants associated with multidrug-resistant organisms (MDROs), including genes for carbapenemases, extended-spectrum b-lactamases (ESBL) and ampC blactamases.
Nucleic acids were extracted from 500 µl of 0.5 McFarland bacterial suspensions using the Roche MagNA Pure 96 DNA and Viral NA Large Volume kit on the MagNA Pure 96 system. 
RESULTS

Analytical performance of the commercial assays
Each of the commercial assays performed well, with sensitivities ranging from 96.2 % (RapidEC CarbaNP) to 100 % (Xpert Carba-R and Acuitas Resistome). The RapidEC CarbaNP failed to detect three OXA-48-positive E. coli isolates and the RESIST-3 O.K.N. failed to detect one NDM-positive K. pneumoniae from an isolate that was highly mucoid. No false positive results were identified, resulting in 100 % specificity for all of the commercial assays evaluated (Table 2) .
Genotype coverage of the commercial assays
Of the four commercial assays evaluated, the RapidEC CarbaNP and Acuitas Resistome Test were able to detect the broadest range of carbapenemase types. Whilst the RapidEC Carba NP was able to detect genotyped isolates in all of the groups included in this study, the genetic Acuitas Resistome test had the additional advantage of being able to distinguish between the different genotypes. The Xpert Carba-R was able to detect and differentiate all of the 'big five' carbapenemase types included in this study (OXA-48, NDM, KPC, VIM and IMP-1), but was unable to amplify OXA-23 and IMI genotypes due to the lack of PPV § 100, 100, 100, 100 100, 100, 100, 100 100, 100, 100, 100 100, 100, 100, 100 NPV § 99.9, 99.8, 98.5, 96.1 99.9, 99.9, 99.2, 98.0 100, 100, 100, 100 100, 100, 100, 100 *Other=carbapenemase genotypes types other than the 'big five'. †Negative=carbapenemase not detected by relevant assay, and carbapenemase-negative ESbL and AmpC-positive isolates. ‡Based on isolates included in study, only targets included in each assay considered as positive for each calculation. §Calculated using absolute sensitivity and specificity values, using Bayes' theorem, for prevalence rates of 1, 5, 28 % (the percentage of Gram-negative isolates that grow on SuperCARBA screening media that are CPO-positive in our setting) and 50 %. TAT, turnaround time; HAT, hands-on time; m, minutes; h, hours. ||IMP-1 only detected by Xpert Carba-R.
primers/probes for these groups. The RESIST-3 O.K.N. had the narrowest range, only detecting and differentiating OXA-48, KPC and NDM genotypes ( Table 2 ). The RapidEC CarbaNP was the only assay included in this study that can detect novel, previously undescribed carbapenemase genotypes.
Suitability for the routine diagnostic laboratory
The turnaround times (TATs) of the assays ranged from 15 min (RESIST-3 O.K.N.) to 24 h (Acuitas Resistome) ( Table 2 ). The RESIST-3 O.K.N. and RapidEC CarbaNP were simple to perform, without the need for additional specialized laboratory equipment. However, for both, reading the results was associated with some subjectivity, in particular for the RapidEC CarbaNP, where although there was a definite colour change associated with all positive results, the intensity of the change did vary; some OXA-48-positive isolates, in particular, were associated with changes from red to only a dark orange. To ensure successful implementation of this assay in the diagnostic laboratory, users must be aware of this limitation and be given appropriate training to gain experience and confidence with the assay. The Xpert Carba-R was also simple to perform and the PCR results were interpreted using the GeneXpert Software, removing any subjectivity from the analysis. In addition, results could be saved electronically without the need for manual entry, facilitating audit and/or review. The Acuitas Resistome test required the most specialized equipment and scientific expertise out of the assays included in this study, but provided the most detailed information on the isolates that were tested, including the presence/absence of multiple genes associated with MDRO (data not shown).
DISCUSSION
Detection of CPOs in the diagnostic laboratory is challenging. Routine diagnostic laboratories must find the right balance in using a testing methodology that reliably detects the genotypes most relevant to their setting and patient population whilst considering acceptable TAT, costs and the available expertise. The Royal Free London NHS Foundation Trust currently uses culture-based methods to detect CPOs; AST results and disc diffusion assays are used to predict the presence of a CPO and all results are confirmed by the Reference Laboratory. This method is associated with a long TAT, particularly for OXA-48-positive CPOs, which are not directly detected using the disc diffusion assays -as a result patients who are negative for CPO carriage can be kept in isolation unnecessarily based on AST results whilst awaiting confirmation testing.
All assays evaluated in the study performed well, with sensitivities ranging from 96.2-100 % and specificities of 100 %. The RapidEC CarbaNP failed to detect three OXA-48-positive CPOs; reduced sensitivity and low negative predictive values associated with OXA-48-type CPOs have been noted previously for this assay [14] , and may be related to poor hydrolysis of the substrate by some OXA-48 enzymes. It has previously been reported that the sensitivity of the RapidEC CarbaNP can be improved by using a heavier inoculum than that described in the product insert without affecting specificity [11] ; however, in this case, the three OXA-48-positive isolates not detected by the RapidEC CarbaNP remained negative when they were tested using a heavier inoculum. Poor hydrolysis of carbapenems, in vitro, by some groups of carbapenemases has been described previously [15] , and this is a limitation of hydrolysis-based assays that users must be aware of.
The RESIST3-O.K.N. failed to detect one NDM that was present in a highly mucoid K. pneumoniae isolate. The significance of the mucoid nature of the isolate currently remains unclear, but it is interesting to note that evaluations of other from-isolate CPO detection assays that rely on a lysis step have reported false-negative and -positive results with highly mucoid bacterial strains [11] . It remains to be determined exactly how capsular material may interfere with non-genetic from-isolate assays, but it is possible that pretreating highly mucoid isolates to neutralize or reduce capsular material may improve results.
The Acuitas Resistome assay provided the most information on our CPO isolates, detailing the presence or absence of genes associated with carbapenemase (25 genes/208 subtypes), ESbL (13 genes/557 subtypes) and AmpC (11 genes/ 147 subtypes). The genetic profile obtained allowed for typing of strains, and isolates from the same patient isolated either over time, or from different sites, gave identical profiles. This illustrates the potential of this assay to be used as an in-house typing tool for resistant Gram-negative organisms. Although not currently suitable for adoption into the routine diagnostic laboratory due to their relatively high cost and the expertise and equipment required, assays that produce this much information clearly have tremendous potential in the healthcare setting. They could, for example, facilitate early identification of transmission events and outbreaks, allowing swift implementation of appropriate infection control procedures.
In our setting, none of the commercial assays evaluated in this study were suitable for standalone testing for the detection of CPOs. They either did not detect the full range of carbapenemase types that we commonly identify (RESIST-3 O.K.N. and Xpert Carba-R), did not provide information on the genotype identified (RapidEC CarbaNP), or are currently not cost-effective or available to perform on-site in the routine diagnostic laboratory (Acuitas Resistome). Therefore, to improve the TATs associated with detection of CPOs, The Royal Free London NHS Foundation Trust plans to introduce an algorithm of testing for screening samples using selective media, followed by a combination of the CPO detection assays. All screening samples will be cultured on SuperCARBA selective media (E&O Laboratories) and all Gram-negative growth will be identified by MALDI TOF MS analysis; to allow detection of all types of carbapenemase, the RapidEC CarbaNP will be performed on Enterobacteriaceae, P. aeruginosa and Acinetobacter spp., and to aid the genotyping of most CPOs, positive isolates will then be tested by either RESIST-3 O.K.N. (Enterobacteriaceae) or Xpert Carba-R PCR (P. aeruginosa and Acinetobacter spp., due to the high prevalence of VIM in these organisms, in our setting) (Fig. 1) . Clinical isolates will be tested for carbapenemase status if they are shown to be non-susceptible to penicillins and cephalosporins and/or penicillins and temocillin by routine susceptibility testing and will feed into the above algorithm at the RapidEC CarbaNP step. Confirmed results will be available within 2 days, compared to our current protocol that takes 7 (KPC and MbL) to 10 (OXA-48) days (Fig. 1) . Based on the isolates included in this study, this algorithm will be highly sensitive and specific and will provide the genotype of over 95 % of the CPOs that are detected. The sensitivity of this algorithm could possibly be improved further by including the previously described adapted RapidEC CarbaNP method [11] , or by testing Enterobacteriaceae isolates with a temocillin MIC>64 mg l
À1
(and therefore possible OXA-48-positive isolates) directly by RESIST-3 O.K.N. To avoid false-negative results, isolates that are highly mucoid when grown in vitro and test negative by the pathway, but are suspected to produce a carbapeneamse by scientists and/or clinicians (based on AST or patient demographics, for example) will be sent to the Reference Laboratory for confirmation. The isolates tested in this study represented, proportionally, the carbapenemase types that are detected within our setting, and it is not clear whether similar results would be obtained using groups of isolates that relate to genotype prevalence in other parts of the world: for example, very few KPC isolates were tested in this study, but this genotype would represent the majority of carbapenemase types tested if these methods were used in areas such as the United States.
Implementing commercially available CPO detection assays into the routine diagnostic laboratory can significantly reduce the TAT to confirmed results compared to culture-based methods that use AST to guide carbapenemase status. Incorporating these assays into an algorithm of testing in settings that see a broad range of carbapenemase genotypes can optimize laboratory workflow and productivity, increase the sensitivity of CPO detection and enable genotyping in the vast majority of cases, whilst enabling early appropriate clinical management and implementation of infection control procedures to improve patient outcomes.
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